论文部分内容阅读
鉴于目前用氯喹治疗疟疾已有抗药性出现,我科于1977年8～12月间试用抗疟新药“复方磷酸咯啶”片剂治疗疟疾48例,疗效满意,现分析报告如下。药品介绍磷酸咯啶(Pyracrine Phosphate)是我国创制的治疗疟疾的化学合成药物,属氨基吖啶的衍生物。实验室证明鼠疟对磷酸咯啶与氯喹的交叉抗药性低微。磷酸咯啶对于良性疟、恶性疟的红细胞内期滋养体,裂殖体均有较强的杀灭作用,能控制临床发作,对红细胞外期原虫及配子体无杀灭作用,不宜作预防和抗复发用。复方磷酸咯啶糖衣片剂(代号7170或6701复方)系上海第十四制药厂产品,每片含
In view of the current resistance to chloroquine treatment of malaria has emerged, our department in trial in August to December 1977 antimalarial drug “compound phosphoric acid pyrimidine tablets” treatment of 48 cases of malaria, with satisfactory results, the analysis is as follows. Drug introduction Pyracrine (Pyracrine Phosphate) is China’s creation of a synthetic drug for the treatment of malaria, is a derivative of amino acridine. Laboratory proved murine malaria on phosphoric acid pyrimidine and chloroquine cross resistance is low. Phosphoric acid methylidine for benign malaria, red blood cells of P. falciparum trophozoites, schizonts have a strong killing effect, can control the clinical attack on erythrocytic protozoa and gametophyte no killing effect, should not be used for prevention and resistance Recurrence. Compound phosphoric acid pyrimethanil tablets (code 7170 or 6701 Compound) Shanghai fourteenth pharmaceutical products, each containing